Provided by Tiger Fintech (Singapore) Pte. Ltd.

SINO BIOPHARM

4.550
+0.0200.44%
Volume:170.43M
Turnover:770.73M
Market Cap:85.36B
PE:21.78
High:4.620
Open:4.540
Low:4.420
Close:4.530
Loading ...

Sino Biopharmaceutical's Drug Study Shows 85.2% Failure-Free Survival Rate for 12 Months

MT Newswires Live
·
11 Mar

BRIEF-Sino Biopharmaceutical Enters Exclusive Cooperation Agreement With Delova Biotech For QP001

Reuters
·
06 Mar

Sino Biopharmaceutical - Entering Into an Exclusive Cooperation Agreement With Delova Biotech for Qp001

THOMSON REUTERS
·
06 Mar

Sino Biopharmaceutical - Expects That Product Will Be Approved by National Medical Products Administration of China for Marketing in Near Future

THOMSON REUTERS
·
06 Mar

BRIEF-Sino Biopharmaceutical Signs Exclusive Strategic Cooperation Agreement With Sciwind Biosciences

Reuters
·
27 Feb

Sino Biopharmaceutical - Signing of an Exclusive Strategic Cooperation Agreement With Sciwind Biosciences

THOMSON REUTERS
·
27 Feb

Sino Biopharmaceutical - Co, Sciwind Biosciences Established Exclusivity on Licensing and Cooperation in 19 Countries for Human Interleukin-29 Project

THOMSON REUTERS
·
27 Feb

Sino Biopharmaceutical Limited's (HKG:1177) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Simply Wall St.
·
11 Feb

Chinese Regulator Approves Sino Biopharmaceul's Tulobuterol Patches for Marketing

MT Newswires Live
·
07 Feb

Sino Biopharmaceutical's Anti-Inflammatory Medication Gets NMPA's Approval for Marketing

MT Newswires Live
·
07 Feb

Sino Biopharmaceutical - Tulobuterol Patches" Obtained Approval for Marketing From National Medical Products Administration of China

THOMSON REUTERS
·
07 Feb

Sino Biopharmaceutical - Approval for Marketing of "Loxoprofen Sodium Cataplasms" From China Nmpa

THOMSON REUTERS
·
07 Feb

Hong Kong stocks close firmer as Lunar New Year holiday kicks in

Reuters
·
28 Jan

Getting In Cheap On Sino Biopharmaceutical Limited (HKG:1177) Might Be Difficult

Simply Wall St.
·
14 Jan

Sino Biopharm Reports Positive Results in NSCLC Drug's Phase III Study

MT Newswires Live
·
27 Dec 2024

BRIEF-Sino Biopharmaceutical Says Positive Results From Phase III Study Of Benmelstobart Injection

Reuters
·
27 Dec 2024

Sino Biopharmaceutical - Benmelstobart Injection Primary Study Endpoint Progression-Free Survival Met

THOMSON REUTERS
·
27 Dec 2024

Sino Biopharm Cleared to Submit Marketing Application for New Indication of Tumor Drug

MT Newswires Live
·
19 Dec 2024

Sino Biopharmaceutical's Cancer Drug Shows Positive Results in Clinical Trials

MT Newswires Live
·
19 Dec 2024

Sino Biopharmaceutical - Permission Obtained to Submit Marketing Application for Indication of Benmelstobart Injection, Others From Nmpa

THOMSON REUTERS
·
19 Dec 2024